2024
November
A tetraspecific NK cell engager armed with IL-2v targets B-NHL
November 27, 2024
To capitalize on the antitumor potential of NK cells for the treatment of B cell non-Hodgkin lymphoma (B-NHL), Demaria et al. developed a clinical-grade tetraspecific NK cell engager (NKCE) that targets NKp46 and CD16a on NK cells and CD20 on tumor cells, and armed it with an IL-2 variant (CD20-NKCE-IL2v). The mechanism and...
SITC - 39th Annual Meeting 2024
November 20, 2024
This week’s extensive special feature covers select talks from the SITC - 39th Annual Meeting 2024 in Houston, TX. We have organized the content by topics below. Keynote lectureRafi Ahmed Harnessing innate immunityEric VivierNicholas Huntington Cancer vaccinesElizabeth M. JaffeeCathy Wu CAR T cells and T cell engagersYvonne ChenMatt MaurerAmanda V. FinckPablo Martinez Fecal...
Novel vaccine strategy uses bacteria to deliver cancer neoantigens
November 13, 2024
In cancer immunotherapy, vaccination with tumor-specific neoantigens can be an effective way to induce antitumor immunity. In recent work, Redenti and Im et al. developed a novel system to deliver neoantigens using an engineered probiotic E. coli Nissle 1917 (EcN) – a bacterial platform that inherently homes to tumors, stimulates immune responses, and...